ArticleDermatology and therapy2025
Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNemolizumab is a humanized monoclonal antibody targeting interleukin-31 receptor A. It has shown efficacy in treating patients with prurigo nodularis (PN). In this study, we characterized the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of nemolizumab in patients with PN and compared its efficacy with that of another approved treatment, dupilumab, using a model-based meta-analysis (MBMA).
methodsWe updated an existing population PK (PopPK) model developed for patients with atopic dermatitis (AD) by incorporating data from four clinical studies. The updated model validated the PK of nemolizumab in patients with PN, confirming its relevance and precision. Furthermore, we developed a population PD (PopPD) model to characterize treatment response and assessed changes in the weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) over time. To conduct an MBMA, we performed a systematic literature search of public databases to identify studies for modeling the success rate of achieving a ≥ 4-point improvement in the PP-NRS and a ≥ 2-point decrease in the Investigator's Global Assessment (IGA).
resultsThe updated PopPK model adequately described the serum concentration profile of nemolizumab in patients with PN, suggesting a similarity in the PK characteristics between AD and PN. The PopPD model successfully described the effects of the placebo and nemolizumab on PP-NRS. Six individual randomized controlled trials were eligible for the MBMA. Model simulations indicated that the success rates for PP-NRS and IGA were consistently higher for nemolizumab compared with dupilumab, up to 24 weeks.
conclusionThe PopPK and PopPD models well described the PK and PD profiles of nemolizumab in patients with PN. MBMA demonstrated that nemolizumab was superior to dupilumab in improving response rates in patients with PN. These findings, derived from pharmacometrics modeling and indirect comparison, may help inform future clinical studies and support the ongoing evaluation of nemolizumab in PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.